Armata Pharmaceuticals, Inc.
Armata Pharmaceuticals, Inc.
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Financial Statements
Values in Millions ($) | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets | |||||||||||||||||
Assets Current | |||||||||||||||||
Cash And Cash Equivalents At Carrying Value | 5 | 9 | 15 | 4 | 12 | 9 | 17 | 26 | 38 | 14 | 24 | 12 | |||||
Prepaid Expense Current | - | - | - | - | - | - | - | - | - | - | 4 | 6 | |||||
Prepaid Expense And Other Assets Current | 1 | 2 | 1 | 1 | 1 | 1 | 3 | 3 | 2 | 2 | - | - | |||||
Other Assets Current | 0 | 0 | 1 | 2 | 0 | 1 | 2 | 1 | 2 | 3 | 8 | 9 | |||||
Assets Current | 6 | 11 | 17 | 8 | 13 | 11 | 22 | 31 | 42 | 19 | 37 | 27 | |||||
Restricted Cash Noncurrent | 4 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 5 | 6 | 6 | 6 | |||||
Property Plant And Equipment Net | 12 | 12 | 13 | 13 | 13 | 13 | 14 | 13 | 13 | 13 | 9 | 9 | |||||
Operating Lease Right Of Use Asset | 33 | 34 | 40 | 41 | 41 | 42 | 42 | 44 | 44 | 45 | 45 | 44 | |||||
Intangible Assets Net Excluding Goodwill | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | |||||
Goodwill | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Other Assets Noncurrent | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | |||||
Assets | 70 | 77 | 90 | 81 | 87 | 86 | 98 | 108 | 120 | 98 | 113 | 101 | |||||
Liabilities And Stockhold… | |||||||||||||||||
Liabilities Current | |||||||||||||||||
Accounts Payable And Accrued Liabilities Current | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 4 | 5 | 6 | 7 | 10 | |||||
Deferred Compensation Liability Current | 3 | 2 | 2 | 2 | 1 | 2 | 2 | 1 | 1 | 1 | 2 | 1 | |||||
Convertible Debt Current | - | - | 48 | 33 | 28 | - | 41 | 48 | 72 | - | - | - | |||||
Operating Lease Liability Current | 5 | 5 | 5 | 4 | 4 | 4 | 5 | 7 | 7 | 9 | 13 | 15 | |||||
Short Term Non Bank Loans And Notes Payable | - | - | - | - | - | - | - | - | - | - | - | 26 | |||||
Other Liabilities Current | 0 | 0 | 1 | 0 | 0 | 1 | 1 | 0 | 0 | 1 | - | - | |||||
Liabilities Current | 9 | 9 | 140 | 120 | 111 | 48 | 118 | 123 | 110 | 16 | 22 | 52 | |||||
Convertible Debt Noncurrent | 255 | 154 | - | - | - | 33 | - | - | - | 59 | 50 | - | |||||
Secured Long Term Debt | 88 | 103 | 15 | - | - | 23 | - | - | 35 | 24 | 22 | - | |||||
Operating Lease Liability Noncurrent | 26 | 27 | 27 | 27 | 27 | 28 | 28 | 28 | 28 | 29 | 28 | 27 | |||||
Deferred Income Tax Liabilities Net | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | |||||
Liabilities | 381 | 295 | 185 | 150 | 141 | 134 | 149 | 154 | 177 | 130 | 125 | 82 | |||||
Stockholders Equity | |||||||||||||||||
Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |||||
Additional Paid In Capital | 305 | 283 | 281 | 281 | 280 | 279 | 279 | 278 | 277 | 276 | 276 | 277 | |||||
Retained Earnings Accumulated Deficit | -617 | -502 | -377 | -351 | -334 | -328 | -330 | -325 | -334 | -309 | -289 | -258 | |||||
Stockholders Equity | -312 | -219 | -96 | -70 | -54 | -48 | -51 | -46 | -57 | -32 | -12 | 19 | |||||
Liabilities And Stockholders Equity | 70 | 77 | 90 | 81 | 87 | 86 | 98 | 108 | 120 | 98 | 113 | 101 | |||||
Common Stock Par Or Stated Value Per Share | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | |||||
Common Stock Shares Authorized | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | 217 | |||||
Common Stock Shares Issued | 37 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | |||||
Shares Outstanding | - | 36 | 4 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | 36 | |||||
Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables
Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables
Custom Table
Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals
Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals
Interactive Financial Visualizations
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Earnings Market Reaction
| Fiscal Year | Q1 1 Month | Q1 2 Month | Q1 3 Month | Q2 1 Month | Q2 2 Month | Q2 3 Month | Q3 1 Month | Q3 2 Month | Q3 3 Month | Q4 1 Month | Q4 2 Month | Q4 3 Month |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.97% | -33.22% | -48.53% | - | - | - | - | - | - | - | - | - |
| 2025 | 43.48% | 57.25% | 84.06% | 15.85% | 26.83% | 99.59% | -15.84% | -1.94% | 0.15% | 33.57% | -6.50% | -11.96% |
| 2024 | -4.90% | -3.85% | 1.75% | -14.02% | -11.44% | -12.92% | -19.49% | -27.57% | -26.47% | -46.37% | -27.93% | 10.61% |
| 2023 | - | - | - | -28.37% | -36.30% | -47.84% | 0.75% | 16.04% | 46.64% | -11.92% | -16.26% | -26.29% |
Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial | ||||||||||||
Subscribe to unlock 17+ years of financial data and 90+ calculated metrics
Subscribe to unlock 17+ years of data and 90+ calculated metrics
Performance and Valuation Metrics
Metrics | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | 2023-06-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Data beyond 3 years is for subscribers only. Unlock 17+ years of financial data Start 7-day free trial |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Liquidity Ratios | |||||||||||||||||
| Current Ratio | 0.64 | 1.19 | 0.12 | 0.06 | 0.12 | 0.23 | 0.19 | 0.25 | 0.38 | 1.16 | 1.67 | 0.52 | |||||
| Quick Ratio | 0.52 | 1.02 | 0.11 | 0.05 | 0.11 | 0.21 | 0.16 | 0.22 | 0.36 | 1.03 | 1.48 | 0.41 | |||||
| Working Capital | -3.28M | 1.72M | -123.02M | -112.57M | -97.37M | -36.94M | -95.82M | -92.28M | -68.33M | 2.69M | 14.70M | -24.73M | |||||
Leverage & Debt | |||||||||||||||||
| Debt to Equity | -1.22 | -1.35 | -1.94 | -2.16 | -2.62 | -2.80 | -2.93 | -3.35 | -3.13 | -4.07 | -10.10 | 4.29 | |||||
| Interest Coverage TTM | - | - | - | - | -14.86 | -9.35 | -9.14 | -7.36 | -13.28 | -34.77 | -35.41 | - | |||||
| Debt Ratio | 5.46 | 3.84 | 2.07 | 1.86 | 1.62 | 1.56 | 1.52 | 1.43 | 1.47 | 1.33 | 1.11 | 0.81 | |||||
Efficiency & Turnover | |||||||||||||||||
| Asset Turnover TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Per Share Metrics | |||||||||||||||||
| Diluted EPS TTM | -7.74 | -4.80 | -1.29 | -0.71 | -0.01 | -0.32 | -1.14 | -1.15 | -2.20 | -1.91 | -1.65 | -0.65 | |||||
| Free Cash Flow Per Share TTM | -0.67 | -0.73 | -0.76 | -0.89 | -1.01 | -1.09 | -1.16 | -1.27 | -1.30 | -1.54 | -1.55 | -1.51 | |||||
| Dividend Per Share TTM | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
Growth Metrics | |||||||||||||||||
| Net Income Growth (1Y) | 66,241.31% | 818.79% | 13.39% | -61.66% | -99.46% | -72.60% | -30.50% | 81.37% | 86.65% | 87.03% | 82.27% | 25.50% | |||||
| EPS Growth (1Y) | 65,613.90% | 816.81% | 13.24% | -61.70% | -99.47% | -72.67% | -30.68% | 80.94% | 86.24% | 77.79% | 82.03% | 25.26% | |||||
Valuation Metrics | |||||||||||||||||
| P/E TTM | -1.32 | -1.31 | -2.30 | -2.68 | -124.01 | -3.54 | -2.07 | -1.48 | -1.90 | -1.69 | -1.82 | -1.11 | |||||
| P/B TTM | -1.20 | -1.04 | -1.13 | -0.99 | -0.98 | -1.39 | -1.68 | -2.16 | -2.67 | -3.65 | -8.74 | 2.15 | |||||
| Market Cap | 374.07M | 227.58M | 107.95M | 68.77M | 52.83M | 66.90M | 85.75M | 99.42M | 151.00M | 116.88M | 108.26M | 41.12M | |||||
| Enterprise Value | 708.09M | 470.43M | 151.14M | 92.49M | 63.45M | 107.56M | 104.48M | 115.80M | 214.69M | 185.67M | 150.50M | 22.94M | |||||
Calculated Values | |||||||||||||||||
| Free Cash Flow TTM | -24.47M | -26.31M | -27.58M | -32.25M | -36.43M | -39.58M | -42.09M | -46.08M | -46.82M | -55.57M | -56.00M | -54.43M | |||||
| Net Debt | 334.02M | 242.84M | 43.18M | 23.73M | 10.62M | 40.67M | 18.74M | 16.38M | 63.69M | 68.78M | 42.24M | -18.18M | |||||
Per-Share and Margin | |||||||||||||||||
| EPS TTM | |||||||||||||||||
| Adjusted EPS TTM | |||||||||||||||||
| Cash Flow Per Share TTM | |||||||||||||||||
| Pretax Margin TTM | |||||||||||||||||
| Stock Comp to Revenue TTM | |||||||||||||||||
Turnover Ratios and Averages | |||||||||||||||||
| Average Assets | |||||||||||||||||
| Average Equity | |||||||||||||||||
| Average Inventory | |||||||||||||||||
| Average Receivables | |||||||||||||||||
| Average Accounts Payables | |||||||||||||||||
| Inventory Turnover TTM | |||||||||||||||||
| Payables Turnover TTM | |||||||||||||||||
| Days Inventory Outstanding TTM | |||||||||||||||||
| Days Payables Outstanding TTM | |||||||||||||||||
| Cash Conversion Cycle TTM | |||||||||||||||||
| Working Capital to Revenue | |||||||||||||||||
| Deferred Revenue to Revenue | |||||||||||||||||
Growth Rates | |||||||||||||||||
| Total Assets Growth (1Y) | |||||||||||||||||
| Total Assets Growth (3Y) | |||||||||||||||||
| Total Assets Growth (5Y) | |||||||||||||||||
| Dividends Paid Growth (1Y) | |||||||||||||||||
| Dividends Paid Growth (3Y) | |||||||||||||||||
| Dividends Paid Growth (5Y) | |||||||||||||||||
| EPS Growth (3Y) | |||||||||||||||||
| EPS Growth (5Y) | |||||||||||||||||
| Net Income Growth (3Y) | |||||||||||||||||
| Net Income Growth (5Y) | |||||||||||||||||
| Net Profit Margin Growth (1Y) | |||||||||||||||||
| Net Profit Margin Growth (3Y) | |||||||||||||||||
| Net Profit Margin Growth (5Y) | |||||||||||||||||
| Net Revenue Growth (3Y) | |||||||||||||||||
| Net Revenue Growth (5Y) | |||||||||||||||||
| Deferred Revenue Growth (1Y) | |||||||||||||||||
| Retained Earnings Growth (1Y) | |||||||||||||||||
Credit, Liquidity, Returns, Payout | |||||||||||||||||
| Cash Ratio | |||||||||||||||||
| Net Working Capital | |||||||||||||||||
| Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to EBITDA TTM | |||||||||||||||||
| Net Debt to Equity | |||||||||||||||||
| Altman A | |||||||||||||||||
| Altman B | |||||||||||||||||
| Altman C | |||||||||||||||||
| Altman D | |||||||||||||||||
| Altman E | |||||||||||||||||
| Altman Z-Score | |||||||||||||||||
| ROA TTM | |||||||||||||||||
| ROE TTM | |||||||||||||||||
| NOPAT TTM | |||||||||||||||||
| ROIC TTM | |||||||||||||||||
| Effective Tax Rate TTM | |||||||||||||||||
| Payout Ratio TTM | |||||||||||||||||
| Dilution Ratio | |||||||||||||||||
| Retained Earnings to Equity | |||||||||||||||||
| Treasury Stock to Equity | |||||||||||||||||
| Treasury Stock Change (1Y) | |||||||||||||||||
| Accrued to Current Liabilities | |||||||||||||||||
Valuation Ratios | |||||||||||||||||
| P/CF TTM | |||||||||||||||||
| Dividend Yield TTM | |||||||||||||||||
| Free Cash Flow Yield TTM | |||||||||||||||||
| EV EBITDA TTM | |||||||||||||||||
| EV EBIT TTM | |||||||||||||||||
| Stock Compensation TTM | |||||||||||||||||
| Adjusted Net Income TTM | |||||||||||||||||
| Billings TTM | |||||||||||||||||
| Total Debt | |||||||||||||||||
| Invested Capital | |||||||||||||||||
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Insider Transactions
Subscribe to unlock 17+ years of financial data
Subscribe to unlock 17+ years of data
Institutional Ownership
Armata Pharmaceuticals, Inc. (ARMP) — SEC Financial Statements & Analysis
Armata Pharmaceuticals, Inc. (ARMP) is a biological products, (no diagnostic substances) company, incorporated in WA. Armata Pharmaceuticals, Inc. trades on NYSE as: ARMP. Based on its latest SEC filing (Form 10-Q, period ending 2026-03-31), Armata Pharmaceuticals, Inc. reported a Debt-to-Equity ratio of -1.22x, a Price-to-Book (P/B) ratio of -1.2 (TTM), at a market cap of $374.07M. Figures below are sourced from SEC EDGAR, as-filed.
- Debt To Equity
- -1.22x
- P/B TTM
- -1.2
- Market Cap
- $374.07M
Data as of 2026-03-31 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Armata Pharmaceuticals, Inc. in?
Armata Pharmaceuticals, Inc. (ARMP) operates in the Biological Products, (No Diagnostic Substances) industry.
What is ARMP's market cap?
Armata Pharmaceuticals, Inc. (ARMP) has a market capitalization of $374.07M as of 2026-03-31.
What exchange does ARMP trade on?
Armata Pharmaceuticals, Inc. (ARMP) trades on the NYSE.
Where is Armata Pharmaceuticals, Inc. incorporated?
Armata Pharmaceuticals, Inc. is incorporated in WA.